Dr Zsuzanna Tabi

2022

• Knight, R. et al. 2022. Oral progenitor cell line-derived small extracellular vesicles as a treatment for preferential wound healing outcome. Stem Cells Translational Medicine 11(8), pp. 861-875. (10.1093/stcltm/szac037)

2021

• Evans, L., Milward, K., Attanoos, R., Clayton, A., Errington, R. and Tabi, Z. 2021. Macrophage plasticity and function in the lung tumour microenvironment revealed in 3D heterotypic spheroid and explant models. Biomedicines 9(3), article number: 302. (10.3390/biomedicines9030302)

2018

• Hill, K., Portman, M. and Tabi, Z. 2018. Meet the researchers: an alternative method of engaging patients with research in mesothelioma. Research Involvement and Engagement 4(1), article number: 33. (10.1186/s40900-018-0119-x)
• Codd, A. S., Kanaseki, T., Torigo, T. and Tabi, Z. 2018. Cancer stem cells as targets for immunotherapy. Immunology 153(3), pp. 304-314. (10.1111/imm.12866)
• Lester, J. F. et al. 2018. A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma - the SKOPOS trial. OncoImmunology 7(12), article number: e1457597. (10.1080/2162402X.2018.1457597)

2017

• Salimu, J., Webber, J., Gurney, M., Al-Taei, S., Clayton, A. and Tabi, Z. 2017. Dominant immunosuppression of dendritic cell function by prostate-cancer-derived exosomes. Journal of Extracellular Vesicles 6(1), article number: 1368823. (10.1080/20013078.2017.1368823)

2016

• Al-Taei, S., Salimu, J., Spary, L. K., Clayton, A., Lester, J. F. and Tabi, Z. 2016. Prostaglandin E2-mediated adenosinergic effects on CD14+ cells: self-amplifying immunosuppression in cancer. OncoImmunology 6(2), pp. 312-318., article number: e1268308. (10.1080/2162402X.2016.1268308)
• Codd, A., Al-Taei, S. and Tabi, Z. 2016. Cross-talk between cancer-initiating cells and immune cells: considerations for combination therapies. Annals of Translational Medicine 4(S1), pp. S56. (10.21037/atm.2016.10.30)
• Welton, J. . L. et al. 2016. Proteomics analysis of vesicles isolated from plasma and urine of prostate cancer patients using a multiplex, aptamer-based protein array. Journal of Extracellular Vesicles 5, article number: 31209. (10.3402/jev.v5.31209)
• Webber, J. P., Spary, L. K., Mason, M. D., Tabi, Z., Brewis, I. A. and Clayton, A. 2016. Prostate stromal cell proteomics analysis discriminates normal from tumour reactive stromal phenotypes. Oncotarget 7, pp. 20124-20139. (10.18632/oncotarget.7716)
• Morgan, R. et al. 2016. HOX transcription factors are potential targets and markers in malignant mesothelioma. BMC Cancer 16(1), article number: 85. (10.1186/s12885-016-2106-7)
• Rintoul, R. C., Rassl, D. M., Gittins, J., Marciniak, S. J., Tabi, Z. and MesobanK collaborators, . 2016. MesobanK UK: an international mesothelioma bioresource. Thorax 71(4), pp. 380-382. (10.1136/thoraxjnl-2015-207496)

2015

• Salimu, J., Spary, L. K., Al-Taei, S., Clayton, A., Mason, M. D., Staffurth, J. and Tabi, Z. 2015. Cross-Presentation of the Oncofetal Tumor Antigen 5T4 from Irradiated Prostate Cancer Cells—A Key Role for Heat-Shock Protein 70 and Receptor CD91. Cancer Immunology Research 3(6), pp. 678-688. (10.1158/2326-6066.CIR-14-0079)
• Chowdhury, R., Webber, J. P., Gurney, M., Mason, M. D., Tabi, Z. and Clayton, A. 2015. Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts. Oncotarget 6(2), pp. 715-731. (10.18632/oncotarget.2711)
• Webber, J. P. et al. 2015. Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes. Oncogene 34(3), pp. 290-302. (10.1038/onc.2013.560)

2014

• Spary, L. K., Salimu, J., Webber, J. P., Clayton, A., Mason, M. d. and Tabi, Z. 2014. Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14+PD-L1+phenotype in prostate cancer. OncoImmunology 3(9), article number: e955331. (10.4161/21624011.2014.955331)
• Webber, J. et al. 2014. Proteomics analysis of cancer exosomes using a novel modified aptamer-based array (SOMAscanTM) platform. Molecular and Cellular Proteomics 13(4), pp. 1050-1064. (10.1074/mcp.M113.032136)
• Spary, L. K. et al. 2014. Enhancement of T cell responses as a result of synergy between lower doses of radiation and T cell stimulation. The Journal of Immunology 192(7), pp. 3101-3110. (10.4049/jimmunol.1302736)

2013

• Al-Taei, S., Banner, R., Powell, N. G., Evans, M., Palaniappan, N., Tabi, Z. and Man, S. T. 2013. Decreased HPV-specific T cell responses and accumulation of immunosuppressive influences in oropharyngeal cancer patients following radical therapy. Cancer Immunology, Immunotherapy 62(12), pp. 1821-1830. (10.1007/s00262-013-1488-5)

2012

• Al-Taei, S. et al. 2012. Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma. Lung Cancer 77(2), pp. 312-318. (10.1016/j.lungcan.2012.03.008)

2011

• Clayton, A., Al-Taei, S., Webber, J. P., Mason, M. D. and Tabi, Z. 2011. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. The Journal of Immunology 187(2), pp. 676-683. (10.4049/jimmunol.1003884)

2010

• Webber, J. P., Steadman, R., Mason, M. D., Tabi, Z. and Clayton, A. 2010. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Research 70(23), pp. 9621-9630. (10.1158/0008-5472.CAN-10-1722)
• Tabi, Z., Spary, L. K., Coleman, S. L., Clayton, A., Mason, M. D. and Staffurth, J. N. 2010. Resistance of CD45RA- T cells to apoptosis and functional impairment, and activation of tumor-antigen specific T cells during radiation therapy of prostate cancer. The Journal of Immunology 185(2), pp. 1330-1339. (10.4049/jimmunol.1000488)

2009

• Mitchell, P. J., Welton, J. L., Staffurth, J. N., Court, J., Mason, M. D., Tabi, Z. and Clayton, A. 2009. Can urinary exosomes act as treatment response markers in prostate cancer?. Journal Of Translational Medicine 7(4), pp. n/a. (10.1186/1479-5876-7-4)
• Navabi, H. et al. 2009. A clinical grade poly I:C-analogue (Ampligen®) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. Vaccine 27(1), pp. 107-115. (10.1016/j.vaccine.2008.10.024)
• Tabi, Z. 2009. Cancer vaccines. In: Lu, Y. and Mahato, R. I. eds. Pharmaceutical Perspectives of Cancer Therapeutics. London: Springer, pp. 365-368.
• Renneson, J. et al. 2009. IL-12 and type I IFN response of neonatal myeloid DC to human CMV infection. European Journal of Immunology 39(10), pp. 2789-2799. (10.1002/eji.200939414)

2008

• Clayton, A., Mitchell, J. P., Court, J., Linnane, S., Mason, M. D. and Tabi, Z. 2008. Human tumor-derived exosomes down-modulate NKG2D expression. Journal of Immunology 180(11), pp. 7249-7258.
• Mitchell, J. P., Court, J., Mason, M. D., Tabi, Z. and Clayton, A. 2008. Increased exosome production from tumour cell cultures using the Integra CELLine Culture System. Journal of Immunological Methods 335(1-2), pp. 98-105. (10.1016/j.jim.2008.03.001)
• Tabi, Z. and Man, S. 2008. Cancer vaccines and immune monitoring (an overview). In: Hayat, M. A. ed. General methods and overviews, lung carcinoma and prostate carcinoma:. Methods of cancer diagnosis, therapy and prognosis Vol. 2. Springer, pp. 129-160., (10.1007/978-1-4020-8442-3)
• Coleman, S. L., Gibbs, A., Butchart, E., Mason, M. D., Jasani, B. and Tabi, Z. 2008. SV40 large T antigen-specific human T cell memory responses. Journal of Medical Virology 80(8), pp. 1497-1504. (10.1002/jmv.21216)

2007

• Clayton, A., Mason, M. D., Mitchell, J. P. and Tabi, Z. 2007. Human tumour-derived exosomes selectively impair lymphocyte responses to Interleukin-2. Cancer Research 67, pp. 7458-7466. (10.1158/0008-5472.CAN-06-3456)

2005

• Clayton, A., Turkes, A., Mason, M. D. and Tabi, Z. 2005. Induction of heat shock proteins in B-cell exosomes. Journal of Cell Science 118(16), pp. 3631-3638. (10.1242/jcs.02494)
• Coleman, S. L., Clayton, A., Mason, M. D., Jasani, B., Adams, M. and Tabi, Z. 2005. Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer. Cancer Research 65(15), pp. 7000-7006. (10.1158/0008-5472.CAN-04-3792)
• Coleman, S. L., Clayton, A., Mason, M. D., Jasani, B., Adams, M. and Tabi, Z. 2005. Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer. Cancer Research 65(15), pp. 7000-6. (10.1158/0008-5472.CAN-04-3792)
• Adams, M. et al. 2005. The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. Vaccine 23(17-18), pp. 2374-2378. (10.1016/j.vaccine.2005.01.014)
• Navabi, H. et al. 2005. Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. Blood Cells, Molecules, and Diseases 35(2), pp. 149-152. (10.1016/j.bcmd.2005.06.008)
• Jasani, B. et al. 2005. Assessment of immunological competence and SV40 specific recall immunity in malignant pleural mesothelioma. Vaccine 23(17-18), pp. 2339-2402. (10.1016/j.vaccine.2005.01.019)
• Clayton, A. and Tabi, Z. 2005. Exosomes and the MICA-NKG2D system in cancer. Blood Cells, Molecules, and Diseases 34(3), pp. 206-213. (10.1016/j.bcmd.2005.03.003)

2004

• Moutaftsi, M., Brennan, P., Spector, S. A. and Tabi, Z. 2004. Impaired lymphoid chemokine-mediated migration due to a block on the chemokine receptor switch in human cytomegalovirus-infected dendritic cells. Journal of Virology 78(6), pp. 3046-3054. (10.1128/JVI.78.6.3046-3054.2004)

2002

• Moutaftsi, M., Mehl, A. M., Borysiewicz, L. K. and Tabi, Z. 2002. Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells. Blood 99(8), pp. 2913-2921. (10.1182/blood.V99.8.2913)

2001

• Tabi, Z., Moutaftsi, M. and Borysiewicz, L. K. 2001. Human cytomegalovirus pp65- and immediate early 1 antigen-specific HLA class I-restricted cytotoxic T cell responses induced by cross-presentation of viral antigens. The Journal of Immunology 166(9), pp. 5695-5703.